Latest Breaking News On - Marketing authorization application - Page 3 : vimarsana.com

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSamantha hilson sandlerChristopherl moertelBetty jayne dahlbergJim cassidyUniversity of minnesota school medicineClinical research divisionAmerican society of clinical oncologyFred hutchinson cancer centerChildren tumor foundationEuropean medicines agencyHealth supervision for children with neurofibromatosis typeNeurofibromatosis programDrug administrationSpringworks therapeutics incDesmoid tumor working group

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of

– Results from pivotal Phase 2b ReNeu trialofmirdametinib in patients with NF1-PN to be presented in an oral presentation –

United statesChristopherl moertelBetty jayne dahlbergJim cassidySamantha hilson sandlerUniversity of washingtonChildren tumor foundationNeurofibromatosis programFred hutchinson cancer centerHealth supervision for children with neurofibromatosis typeEuropean commissionClinical research divisionSpringworks therapeutics incEuropean medicines agencyUs department of commerceAmerican society of clinical oncology

Royalty Pharma and Cytokinetics Announce Expanded Strategic

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,.

United statesPablo legorretaJohnson tremfyaNovarti promactaMaiwald gmbJohnson imbruvicaOmecamtiv mecarbilFadyi malikRoberti blumRoche evrysdiDiane weiserNational medical products administrationDrug administrationGoodwin procterMorrison foerster llpEuropean medicines agency

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

JENA, Germany, May 21, 2024 InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American.

San diegoUnited statesInflarx gmbRegina lutzCamilla chongLaurie doyleJan medinaKatja arnoldGlobenewswire incInflarx pharmaceuticals incInflarx commitment programDrug administrationAmerican thoracic societyInternational conferenceEuropean medicines agencyMc services

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus trial;.

United kingdomUnited statesCity ofJulia wilsonJune decSusana noonanOlivia manserRavi raoJohnh johnsonEuropean medicines agencyUniversity college londonEuropean hematology associationCardinal healthNature communicationsSa noonan communicationsAmerican society of clinical oncology